Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereof
US11512137B2 · kind B2 · utility
5Cited by
6References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 11, 2020 |
| Grant date | Nov 29, 2022 |
| Priority date | — |
| Expiry date | May 11, 2040 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/70596
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.